Amyotrophic Lateral Sclerosis (ALS) Treatment Market By Drug Type (Riluzole, Edaravone) - Growth, Share, Opportunities & Competitive Analysis, 2015 – 2025
Amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease is a neurological disease that causes death of nerve cells that control voluntary muscles. Factors such, increase in incidence of ALS, strong pipeline molecule, favorable reimbursement policies in some countries and expected launch of newer medication would drive the growth of ALS treatment market globally.
The report titled “Amyotrophic Lateral Sclerosis (ALS) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall ALS treatment market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug type (Riluzole, Edaravone and Other) and different geographical regions. Geographically, the global ALS treatment market is studied for the following regional markets:
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Rest of Europe
- Asia-Pacific
- China
- Japan
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of LATAM
- Middle East and Africa
- GCC
- Rest of MEA
Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, opportunities and pipeline analysis assists the readers for understanding the ongoing trends in the global ALS treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global ALS treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global ALS treatment market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global ALS treatment market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Based on drug type, the global amyotrophic lateral sclerosis (ALS) treatment market is segmented as follows:
- Riluzole
- Edaravone
- Other
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die. According to Centers for Disease Control and Prevention (CDC), 14,000 - 15,000 Americans had ALS in 2016. Factors such as increasing treatment awareness, strong pipeline molecules, rising geriatric population and recent approval of new treatment medication is expected to drive the growth of ALS treatment market globally. Currently, there is no cure for ALS however, treatments are available to control symptoms and prevent unnecessary complications. The U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of ALS it includes Riluzole (Rilutek) and Edaravone (Radicava). Other medications are prescribe to control ALS symptoms such as muscle cramps and spasms, spasticity, constipation, fatigue, excessive salivation, excessive phlegm, pain, depression and sleep problems. It is studied that in the base year 2016, Riluzole (Rilutek) was major revenue generating segment due to high compliance because it is the only medication used in treatment of ALS which works by reducing levels of a chemical messenger in the brain (glutamate) that often present in higher levels in people with ALS. Patent expiry of Rilutek in 2013 has negatively impacted the growth of ALS treatment market. On the other hand, recently approve Radicava expected to show highest growth rate during forecast period due to its applicability and higher cost are expected to drive market growth during forecast period. Moreover expected launch of ALS treatment molecule such as AB-1010 (masitinib), Methycobal (mecobalamin), Arimoclomol, CK-2017357 (CK-357, tirasemtiv) would assist market growth during forecast period.
For the purpose of this study, the global amyotrophic lateral sclerosis (ALS) treatment market is categorized into:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
It is observed that, in the base year 2016, North America dominated the ALS treatment market in terms of revenue due to the factors such as upsurge in funding by government agencies and private organizations in healthcare system, increase in prevalence of the neurological diseases and higher treatment awareness are assisting market growth in North America. According to National ALS Registry, in year 2016, more than 12,000 people in the United States have a definite diagnosis of ALS, prevalence of 3.9 cases per 100,000 persons in the U.S. general population. According to National Organization for Rare Disorders (NORD), ALS is a rare disorder, approximately 5,000 new cases are diagnosed each year in the United States. Even though Riluzole is expensive, insurance policies such as Medicare, also the National Organization for Rare Diseases also support covers Riluzole. Furthermore Covis Patient Assistance Program helps U.S. citizens or residents who don't have a health care plan or have been denied coverage for treatment which is further driving the market growth in North America. It is estimated that, Asia Pacific will show highest growth rate during forecast period due to increasing healthcare awareness, increasing partnership of key players such as Biogen, Avicena, Mitsubishi Tanabe, and Sanofi with local manufacturer, populous countries and developing economic condition would fuel ALS treatment market growth.
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Snapshot
2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, Drug Type
2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share, by Geography, 2016 (Value %)
Chapter 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment Market
3.4 Epidemiology of Amyotrophic lateral sclerosis (ALS)
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Chapter 4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type
4.1 Overview
4.2 Top 3 Countries
4.3 Riluzole
4.4 Edaravone
4.5 Other
Chapter 5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.2.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.4.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.5.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015- 2025 (US$)
5.6.2 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015- 2025 (US$)
Chapter 6 Company Profiles
6.1 AB Science
6.2 Avicena Group
6.3 Biogen
6.4 BrainStorm Therapeutics
6.5 Covis Pharmaceutical Inc.
6.6 Cytokinetics Inc.
6.7 Eisai Co. Ltd.
6.8 GlaxoSmithKline plc.
6.9 Ionis Pharmaceuticals, Inc.
6.10 Mitsubishi Tanabe Pharma Corp.
6.11 Neuralstem Inc.
6.12 Neuraltus Pharmaceuticals Inc.
6.13 Newron Pharmaceuticals S.p.A.
6.14 Pharnext SAS
6.15 Q-Therapeutics Inc.
TABLE 1 Market Positioning of Key Players in Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market
TABLE 2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 3 Top 3 Countries in Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2015 – 2025 (US$ Mn)
TABLE 4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 6 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 8 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 10 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 12 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 14 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 15 AB Science: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Avicena Group: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Biogen: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 BrainStorm Therapeutics: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Covis Pharmaceutical Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Cytokinetics Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Eisai Co. Ltd.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Ionis Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Mitsubishi Tanabe Pharma Corp.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 25 Neuralstem Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 26 Neuraltus Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 27 Newron Pharmaceuticals S.p.A.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 28 Nutra Pharma Corp.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 29 Pharnext SAS: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 30 Q-Therapeutics Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
FIG. 1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Research Methodology
FIG. 2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Drug Type, 2016 (US$ Mn)
FIG. 3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, by Geography, 2016
FIG. 5 Global Riluzole Market, 2015 – 2025 (US$ Mn)
FIG. 6 Global Edaravone Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Other ALS Treatment Drugs Market, 2015 – 2025 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)